Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.
about
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionSynthetic DNA vaccine strategies against persistent viral infectionsControl of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed bloodsiRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals.Influence of dendritic cells on viral pathogenicityRegulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART.Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapyA randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapyRepeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefitDendritic cell-based human immunodeficiency virus vaccine.Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181.A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.Regulatory T cells in HIV immunotherapyAutologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapyA therapeutic dendritic cell-based vaccine for HIV-1 infection.Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infectionTherapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals.Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.Harnessing human dendritic cell subsets for medicine.Dendritic cell immunotherapy for HIV infection: from theory to reality.Immunotherapeutic restoration in HIV-infected individuals.Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?Generation of immunogenic and tolerogenic clinical-grade dendritic cells.Therapeutic vaccines against HIV infection.Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.Therapeutic and prophylactic DNA vaccines for HIV-1.Dendritic cell dysregulation during HIV-1 infection.Dendritic cell based vaccines for HIV infection: the way ahead.mRNA-based dendritic cell vaccines.New challenges in therapeutic vaccines against HIV infection.A novel and simple method for generation of human dendritic cells from unfractionated peripheral blood mononuclear cells within 2 days: its application for induction of HIV-1-reactive CD4(+) T cells in the hu-PBL SCID mice.Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses.Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine?Highlights from the Third Biennial Strategies for an HIV Cure Meeting: 14-16 November 2016, Bethesda, MD, USA.Postconditioning hormesis put in perspective: an overview of experimental and clinical studies.Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV.Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection.
P2860
Q26775082-D0E82F97-B3D3-494B-A223-67DB9774FC0CQ27016078-CDD9D642-B2B1-4A58-9CAC-054C03DCF648Q28472597-F5A6492B-C0BC-472B-B59E-CCDFE4DF0FB6Q33475710-19C81277-57D5-453E-A838-A6D012B660C0Q33489629-3AA67F60-12CF-4364-9572-2DC9D216D8B8Q33547403-517AC355-1D55-4F6F-97DB-FDA34F507A9CQ33637584-D716B776-F8F4-486C-994B-0157A5477145Q33645564-E4B04CAD-F1A2-49E1-9F7C-D9933EA30779Q33698152-4EA1743D-ADBB-4CF6-82DF-04AF2880C59BQ33874652-CBF29FEB-D5BA-4CC7-BF88-7A0F46F0B670Q34150457-C2FB09EC-DDE9-4651-84A3-8E1C11B3100AQ34646987-1B7C57D9-C8B8-46F7-A6DC-A97FFD514607Q34725547-B33C2C51-A1AA-403F-91EC-D8CD0471BF5DQ34749218-3492F7AA-2FE0-4C46-83B2-8278C8AA0AA8Q34764392-AD68E7BD-96BC-4632-84C4-B6B0F3C63ACAQ35731394-C4025163-DCE1-4149-B4B3-D2F109DD21CEQ36745227-7089AD45-7AE6-4927-B02F-B5450FF22703Q37099222-86A4F407-D7DA-4AA7-A1E0-122550B7E446Q37215858-5E7DFF0B-CD62-4DE5-BB1D-CB9EE12E8D60Q37381097-EF8169CB-E259-4161-9F67-5097F3113FDFQ37700841-917616EF-3A7A-4951-AD27-8098817E58BEQ37773251-3B883B2D-2A80-49FE-BE2F-3EA20571D6D8Q37842335-6E28E9C0-526B-43F3-BA14-4E6A8C747279Q37945301-F9C747D6-8015-41DA-811C-43D9BC2793C7Q37959362-419F95FB-E46C-48DF-BBE9-74DE0F567344Q38013505-29EFE5B2-856A-4F18-BBA3-FF41884E83FBQ38031222-25E78929-9C32-4F9E-8FB7-3CAA6960EDE2Q38088037-2B764328-92F3-4B2B-B96E-B39748C10CCFQ38114911-B57351F6-BC60-4D5F-AD33-E07E7E8C0EE5Q38126373-EA8AA983-37EC-43FB-B46E-3412E5254B3DQ38246769-BE0C300F-89F5-443A-B082-D04E63987305Q38692205-30255589-29FF-4E15-90B7-8DC9D5BBCFEEQ39338676-6A9A779F-C7A1-4584-BF77-8DCD47FADAEAQ39550595-784FF0F1-D14C-4EFA-97E9-A68E5C25147DQ41217724-6C0DBDBB-9006-428D-8648-BA904EF98572Q42252625-D33D759E-B72E-4D66-998B-5AC2B1B83A82Q42318283-0498C8EF-DE63-450D-87E7-62538A59313AQ42764966-1B4A9648-C294-459D-BF6C-66477197AE95Q43294881-F8B20968-7670-4CB3-9762-27EA625C5518Q44606374-F02A58AA-B145-4A33-B801-170F81F52B62
P2860
Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Therapeutic immunization with ...... in HIV-1-infected individuals.
@ast
Therapeutic immunization with ...... in HIV-1-infected individuals.
@en
type
label
Therapeutic immunization with ...... in HIV-1-infected individuals.
@ast
Therapeutic immunization with ...... in HIV-1-infected individuals.
@en
prefLabel
Therapeutic immunization with ...... in HIV-1-infected individuals.
@ast
Therapeutic immunization with ...... in HIV-1-infected individuals.
@en
P2093
P2860
P356
P1476
Therapeutic immunization with ...... in HIV-1-infected individuals.
@en
P2093
Cara Wilson
Charles R Rinaldo
Nancy C Connolly
Sharon A Riddler
Theresa L Whiteside
Venkatswarlu Kondragunta
P2860
P304
P356
10.1128/CVI.00221-07
P577
2007-10-17T00:00:00Z